Tesamorelin – 10MG

What Is Tesamorelin? Benefits & Overview

Tesamorelin is a synthetic GHRH (Growth Hormone Releasing Hormone) analog and the only FDA-approved peptide for visceral fat reduction. Available in Canada from Reviv Peptides as a 10 mg lyophilized vial, Tesamorelin stimulates pulsatile GH release with a physiological pattern that preserves the feedback loop and avoids IGF-1 overshoot — delivering clinically validated reductions in visceral adipose tissue (VAT) without the metabolic side effects of exogenous HGH.

Its full GHRH sequence gives it complete agonism at the GHRH receptor, producing robust, physiologically pulsatile GH release that closely mimics endogenous secretion patterns.

Tesamorelin Benefits & Uses

• GHRH receptor agonism and GH pulse stimulation research
• Visceral and truncal fat reduction models
• Metabolic syndrome and body composition studies
• IGF-1 axis regulation and downstream anabolic signalling
• Cardiovascular lipid profile research
• Cognitive function in GH-deficient and ageing models

How Tesamorelin Works

Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile GH secretion that mirrors physiological patterns more closely than synthetic GH administration. Elevated GH drives hepatic IGF-1 production, which mediates lipolysis in visceral adipose tissue — a key mechanism in the FDA-approved indication. Unlike exogenous GH, Tesamorelin preserves the natural feedback axis, reducing risk of GH excess-related artefacts in long-term research models.

Tesamorelin 10mg Vial Specifications

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S
• Molecular Weight: 5,136.8 Da
• Purity: ≥98% (third-party HPLC verified)
• Form: Lyophilized powder
• Vial Size: 10 mg
• Storage: −20 °C (long-term); 4 °C (short-term)
• Reconstitution: Bacteriostatic water

Why Buy Tesamorelin from Reviv Peptides

Reviv Peptides supplies Tesamorelin to Canadian research institutions and licensed researchers with third-party verified purity, full CoA documentation, and discreet Canada-wide shipping.

Tesamorelin Canada FAQs

Is Tesamorelin FDA-approved?

Yes. Tesamorelin (Egrifta®) is FDA-approved for treatment of HIV-associated lipodystrophy.

How does Tesamorelin differ from CJC-1295?

Both are GHRH analogs, but Tesamorelin uses the full 44-amino acid GHRH sequence for complete receptor engagement, while CJC-1295 uses a shorter analog with a DAC modification for extended half-life. Tesamorelin more closely mimics physiological GH secretion patterns.

Is Tesamorelin available in Canada?

Reconstitution & Dosing Guide

How to Reconstitute

Add 3.0 mL of bacteriostatic water to the vial. Inject the water slowly down the inside wall of the vial — do not inject directly onto the powder. Gently swirl until fully dissolved; do not shake. This yields approximately 3.33 mg/mL. Store the reconstituted vial at 4 °C and use within 28 days.

Low Starting Dose

• Dose per injection: 1 mg (1,000 mcg) — 30 units (0.30 mL) on a U-100 insulin syringe
• Frequency: Once daily, subcutaneous injection (evening)
• Cycle length: 12–26 weeks

FDA-approved therapeutic dose is 2 mg daily; start at 1 mg for the first week.

Start at the lowest effective dose and adjust based on individual response. Consult a qualified healthcare professional before use.